Project
CAHmelia SPR001-204
Ongoing - recruitment active · 2021 until 2025
Bilz Stefan, Krull Ina, Räss Andrea
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2021
End Date
2025
Financing
Industry
Study Design
Randomized, Double-Blind, Placebo-Controlled Study
Brief description/objective
CONFIDENTIAL Page 1 of 112
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia